AustraliaHealth

Nexalis Therapeutics (ASX:NX1) announced a clinical breakthrough with the screening of the first patient in its Phase 2 clinical trial for IRX-211.

Radiopharm Theranostics (ASX:RAD) unveiled initial data from its Phase 1 "HEAT" first-in-human clinical trial.

4DMedical (ASX:4DX) announced a new strategic contract with pharmaceutical giant GlaxoSmithKline.

Monash IVF Group (ASX:MVF) has rejected a revised, unsolicited takeover bid from a consortium led by Genesis Capital and Washington H. Soul Pattinson (ASX:SOL).

Orthocell (ASX:OCC) completed its first Remplir surgical case in the US DoD/VA network.

Immuron (ASX:IMC) recorded a double-digit increase in global sales for the third quarter of fiscal year 2026.

Radiopharm Theranostics (ASX:RAD) announced the completion of enrolment for its US Phase 2b imaging trial of RAD 101.

Xenitra (ASX:XEN) announced the 100% acquisition of Hong Kong Fukang Trading.

PYC Therapeutics (ASX:PYC) advances its PYC-001 drug candidate to multiple-dose testing for blinding eye disease ADOA.

FDA granted Immutep (ASX:IMM) Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma.

Orthocell (ASX:OCC) secured approval to supply its Remplir nerve repair device to 221 DoD and Veterans Affairs hospitals.

Genetic Signatures (ASX:GSS) has signed a multi-year supply agreement with Denmark's Hvidovre Hospital.